Trastuzumab in pregnancy associated with poor fetal outcome.
Witzel
I D
ID
Müller
V
V
Harps
E
E
Janicke
F
F
Dewit
M
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D019559:Capillary Leak Syndrome / Q000209:etiology*; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D020345:Enterocolitis, Necrotizing / Q000209:etiology; D017809:Fatal Outcome; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000209:etiology*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D016104:Oligohydramnios / Q000139:chemically induced*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D012127:Respiratory Distress Syndrome, Newborn / Q000209:etiology*; D000068878:Trastuzumab; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014747:Vinblastine; D000068878:Trastuzumab; D000077235:Vinorelbine